SB8: A Bevacizumab Biosimilar

SB8 is a biosimilar of the monoclonal anti-VEGF antibody bevacizumab and is approved in the EU for use in the same types of cancer as bevacizumab. SB8 has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab and pharmacokinetic equivalence was shown in healthy vol...

Descripción completa

Detalles Bibliográficos
Autor principal: Syed, Yahiya Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Adis Biosimilar Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733936/
https://www.ncbi.nlm.nih.gov/pubmed/33206282
http://dx.doi.org/10.1007/s11523-020-00776-0
Descripción
Sumario:SB8 is a biosimilar of the monoclonal anti-VEGF antibody bevacizumab and is approved in the EU for use in the same types of cancer as bevacizumab. SB8 has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab and pharmacokinetic equivalence was shown in healthy volunteers and patients with non-small cell lung cancer (NSCLC). SB8 demonstrated equivalent clinical efficacy to reference bevacizumab in patients with metastatic or recurrent nonsquamous NSCLC, with similar tolerability, safety and immunogenicity profiles.

Ejemplares similares